ZPRÁVA O PRŮBĚHU KLINICKÉHO HODNOCENÍ CoVigi (22. 3. 2021 – 21. 3. 2022)
| Title in English | CoVigi CLINICAL EVALUATION PROGRESS REPORT (22/03/2021 – 21/03/2022) |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| Web | COVIGI |
| Description | The clinical trial CoVigi aims to obtain information on the efficacy and safety of COVID-19 vaccines by determining antibody levels and cellular immunity, collecting data on adverse events and effects, and monitoring the incidence of COVID-19 disease over a period of two years. In addition, the circulating immune profile of oncological patients is monitored, and the determined objectives and parameters are evaluated in connection with the type of oncological treatment administered. It is planned to enroll 565 adult subjects in 3 study centers. The trial's sponsor is Masaryk University. |
| Related projects: |